News

Evoxac eases dry mouth symptoms in Sjögren’s patients, review finds

Treatment with Evoxac (cevimeline hydrochloride) significantly improved salivary flow and eased symptoms of dry mouth in people with Sjögren’s syndrome, according to a meta-analysis of three clinical trials. These findings suggest that Evoxac, an approved Sjögren’s treatment, is a “promising therapeutic option, particularly for individuals with mild to moderate…

FDA grants breakthrough therapy status to nipocalimab for Sjögren’s disease

Johnson & Johnson’s antibody-based therapy candidate nipocalimab has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for treating adults with moderate to severe Sjögren’s disease. This status is meant to accelerate the development and regulatory review of investigational therapies intended to treat serious…